MedTrace Logo

A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

NCT01925157 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2015-10-01

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3090106 in healthy participants and in participants with RA who are having an inadequate response to methotrexate (MTX). The study will investigate how the body processes the study drug and how the study drug affects the body. The study will last about 3 months for each participant.

Conditions

Interventions

BIOLOGICAL

LY3090106 - SQ

Administered SQ.

BIOLOGICAL

LY3090106 - IV

Administered IV.

BIOLOGICAL

Placebo - SQ

Administered SQ.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLilly (1-877-285-4459) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-01-31
Completion
2015-09-30

Countries

  • Bulgaria
  • Moldova
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01925157 on ClinicalTrials.gov